Evaluation of Global Post-Outbreak COVID-19 Treatment Interventions: A Systematic Review and Bibliometric Analysis of Randomized Controlled Trials DOI Creative Commons
Mohammed Alfaqeeh, Neily Zakiyah, Auliya A. Suwantika

et al.

Journal of Multidisciplinary Healthcare, Journal Year: 2023, Volume and Issue: Volume 16, P. 4193 - 4209

Published: Dec. 1, 2023

The outbreak of COVID-19 has led to a global pandemic with millions cases and deaths. Many randomized controlled trials (RCTs) were conducted establish effective therapies. However, the methodological quality these is paramount, as it directly impacts reliability results. This systematic review bibliometric analysis aim assess approach, execution diversity, trends, distribution treatment RCTs post-outbreak, covering period from second wave onward up present.We utilize articles three electronic databases published September 1, 2020, April 2023. Inclusion exclusion criteria applied identify relevant RCTs. Data extraction involved collection various study details. Risk Bias (RoB) 2 tool assessed quality, while implementation variability was evaluated against registration information. Bibliometric analysis, including keyword co-occurrence country distribution, used VOSviewer Tableau software.Initially, 501 studies identified, but only 22 met inclusion criteria, which 19 had assessment revealed deficiencies in five main domains: randomization process (36%), deviations intended interventions (9%), missing outcome data (4%), measurement (18%), selection reported results (4%). An alignment between research protocols common eight critical aspects. findings showcased collaboration RCTs, Iran Brazil prominently contributing, illuminated prominent trends terms titles abstracts.This offers valuable insights into evaluation scarcity high-quality highlights importance enhancing trial rigor transparency health emergencies.

Language: Английский

Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2 DOI
Roopal Garg,

Raveen Kumar,

Ritika Srivastava

et al.

Medicinal Chemistry Research, Journal Year: 2024, Volume and Issue: 33(6), P. 869 - 884

Published: May 28, 2024

Language: Английский

Citations

1
Paxlovid reduces the 28-day mortality of patients with COVID-19: a retrospective cohort study DOI Creative Commons

Kaican Zong,

Xu Li, Chun Huai Luo

et al.

BMC Infectious Diseases, Journal Year: 2024, Volume and Issue: 24(1)

Published: Aug. 1, 2024

Abstract Purpose In this study, we aim to explore the efficacy of paxlovid on reducing mortality COVID-19 patients in clinical setting, especially whether modifies risk death these severe and critical patients. Methods Our retrospective cohort study was conducted medical records patients, consecutively admitted for five hospitals Chongqing, China from Dec 8, 2022 Jan 20, 2023. Based received during their hospitalization, were grouped as group non-paxlovid group. We used 1:1 ratio propensity score matching (PSM) our adjust confounding factors differences between groups. Statistical analysis performed by SPSS 23.0. The 28-day two groups its influencing main results focused on. Results There 1018 included cohort. With PSM, each 237 showed that using have a lower overall population either before PSM (OR 0.594, 95% CI 0.385–0.917, p = 0.019) or after 0.458, 0.272–0.774, 0.003) with multivariable adjusted logistic regression models. Meanwhile, subgroup, it similar findings.With treatment, significantly subgroup both (28% vs.41%, 0.008) (19% vs.32%, 0.007). Conclusion Paxlovid can reduce patients.This distinguished who benefit more treatment.

Language: Английский

Citations

1
Synthesis, characterization, DFT and molecular docking study of an antiviral drug, the crystallized 6-methoxylated derivative of favipiravir, in the presence of an iron (III) Lewis acid. DOI
Aymen Labidi,

Taissir AISSA,

Outaf Fliss

et al.

Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: 1321, P. 139920 - 139920

Published: Sept. 10, 2024

Language: Английский

Citations

1
N-acetylcysteine as adjuvant therapy for hospitalized Covid-19 patients: A single-center prospective cohort study. DOI
Siamak Afaghi,

Negin Moghimi,

Nasser Malekpour Alamdari

et al.

PubMed, Journal Year: 2023, Volume and Issue: 14(3), P. 543 - 552

Published: Jan. 1, 2023

Whilst over two years have passed since the COVID-19 pandemic's emergence, proper management of disease remains challenging. N-acetylcysteine (NAC) as a potentially effective therapeutic option has been suggested by studies, while exact clinical role this agent is yet to be evaluated.This prospective case-control study was conducted in major referral respiratory center Tehran, Iran. We enrolled 217 patients treated with an intravenous daily dose 1500 mg NAC case group; and 245 control who did not receive NAC. Two groups were matched based on other treatments, socio-demographics, medical history, comorbidities.After ten days adjuvant therapy NAC, group had median room-air SpO2 91% 88%, respectively (P=0.02). Also, FiO2 ratio 463 421 groups, (P=0.01). Furthermore, group's hospitalization period three shorter (P=0.002). Further, cough, dyspnea, decreased appetite reported significantly lower incidence (P=0.03, 0.001, 0.008).We showed that hospitalized could shorten hospital stay improve some symptoms; however, it does remarkably risk ICU admission 28 in-hospital mortality rate.

Language: Английский

Citations

3
Evaluation of Global Post-Outbreak COVID-19 Treatment Interventions: A Systematic Review and Bibliometric Analysis of Randomized Controlled Trials DOI Creative Commons
Mohammed Alfaqeeh, Neily Zakiyah, Auliya A. Suwantika

et al.

Journal of Multidisciplinary Healthcare, Journal Year: 2023, Volume and Issue: Volume 16, P. 4193 - 4209

Published: Dec. 1, 2023

The outbreak of COVID-19 has led to a global pandemic with millions cases and deaths. Many randomized controlled trials (RCTs) were conducted establish effective therapies. However, the methodological quality these is paramount, as it directly impacts reliability results. This systematic review bibliometric analysis aim assess approach, execution diversity, trends, distribution treatment RCTs post-outbreak, covering period from second wave onward up present.We utilize articles three electronic databases published September 1, 2020, April 2023. Inclusion exclusion criteria applied identify relevant RCTs. Data extraction involved collection various study details. Risk Bias (RoB) 2 tool assessed quality, while implementation variability was evaluated against registration information. Bibliometric analysis, including keyword co-occurrence country distribution, used VOSviewer Tableau software.Initially, 501 studies identified, but only 22 met inclusion criteria, which 19 had assessment revealed deficiencies in five main domains: randomization process (36%), deviations intended interventions (9%), missing outcome data (4%), measurement (18%), selection reported results (4%). An alignment between research protocols common eight critical aspects. findings showcased collaboration RCTs, Iran Brazil prominently contributing, illuminated prominent trends terms titles abstracts.This offers valuable insights into evaluation scarcity high-quality highlights importance enhancing trial rigor transparency health emergencies.

Language: Английский

Citations

3